BioNexus Gene Lab Corp. (BGLC) is a Healthcare stock trading at $2.59 (as of 2026-06-18), with a market capitalization of $4.17M and a trailing P/E of -23.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
BioNexus Gene Lab Corp. operates through subsidiaries that (1) wholesale chemical raw material products in Malaysia, Indonesia, Vietnam, and other Southeast Asian countries, and (2) develop and provide non-invasive liquid biopsy tests for early detection of biomarkers. Chemrex Corporation Sdn. Bhd. supports the chemicals business, while BioNexus Gene Lab Sdn. Bhd. supports the diagnostic tests.